Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C

Internal Medicine
Chisa KondoChoitsu Sakamoto

Abstract

Pegylated-interferon/ribavirin (peg-IFN/RBV) therapy with a protease inhibitor is the standard therapy for genotype 1b chronic hepatitis C. Despite improving treatment outcomes, patients with thrombocytopenia are often difficult to treat because interferon commonly exacerbates thrombocytopenia. In this study, partial splenic embolization (PSE) was performed in patients with hypersplenism-induced thrombocytopenia to determine the effectiveness of this method as a potential treatment. Patients were pretreated with PSE and then received triple combination therapy. The safety and efficacy of PSE was evaluated. Eighteen patients were analyzed, including 12 patients with the interleukin 28B (IL28B) major genotype and 12 patients with the inosine triphosphatase (ITPA) major genotype. The median embolization rate with PSE was 70% (range: 40-85%). PSE increased the patients' platelet counts from 71.5×10(3) /μL (53-99×10(3) /μL) to 121.5×10(3) /μL (70-194×10(3) /μL; p=0.0002). The patients' platelet counts fluctuated above 50×10(3) /μL during the treatment. Specifically, the increase in the platelet count was significantly associated with the ITPA major genotype compared with the minor genotype (p=0.0057 at 2 weeks, p=0.0031 at 3 weeks, ...Continue Reading

References

Oct 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·K KiyosawaR H Purcell
Dec 18, 1986·The New England Journal of Medicine·J H HoofnagleE A Jones
May 15, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A KasaharaK Okita
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Oct 11, 2005·European Journal of Gastroenterology & Hepatology·José R ForunySantiago Moreno
Oct 21, 2006·Journal of Viral Hepatitis·Beat HelblingUNKNOWN Swiss Association for the Study of the Liver (SASL)
Nov 30, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Gregory T EversonUNKNOWN HALT-C Trial Group
Jun 15, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lisa I BackusLarry A Mole
Jul 29, 2008·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuhiro MiyakeMamoru Hirohata
Nov 18, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Savino BrunoPatrick Marcellin
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Jun 28, 2011·Journal of Hepatology·Alexander J ThompsonAndrew J Muir
Sep 16, 2011·The New England Journal of Medicine·Kenneth E ShermanUNKNOWN ILLUMINATE Study Team
Apr 19, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alexander J Thompson, John G McHutchison
Jul 10, 2013·Nature Medicine·David L Thomas
Oct 9, 2013·Alimentary Pharmacology & Therapeutics·E OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group

❮ Previous
Next ❯

Citations

Jun 9, 2016·World Journal of Gastroenterology : WJG·Ai NakagawaKatsuhiko Iwakiri
Feb 6, 2020·Journal of Vascular and Interventional Radiology : JVIR·Abhinav TalwarRiad Salem

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.